Revolution Medicines reported that its pan-RAS inhibitor enabled patients with an aggressive form of pancreatic cancer to survive roughly six months longer on average compared to those receiving chemotherapy, meeting the primary objective of its phase 3 trial.
The study focused on individuals with metastatic pancreatic ductal adenocarcinoma (PDAC) whose disease had progressed after prior treatment. Participants were randomized to receive either a once-daily 300 mg oral dose of daraxonrasib or standard intravenous chemotherapy.
Across the full study population, which included patients with different RAS mutations as well as those without them, median overall survival reached 13.2 months for those treated with daraxonrasib, compared with 6.7 months for patients in the chemotherapy group, according to an April 13 announcement.
The trial’s primary endpoints included overall survival (OS) and progression-free survival (PFS) in patients with RAS G12 mutations. While Revolution Medicines confirmed that both primary and key secondary endpoints were achieved, it did not disclose detailed PFS results.
The company also noted that daraxonrasib demonstrated a generally favorable safety profile, with side effects considered manageable and no new safety concerns identified in the PDAC population.
Revolution Medicines plans to submit the OS and PFS data to regulators as part of its approval package, including through the U.S. Food and Drug Administration’s national priority voucher program. The findings are also expected to be presented at the American Society of Clinical Oncology Annual Meeting 2026 in late May.
Mark Goldsmith, CEO of Revolution, said in a release that in the pivotal study, daraxonrasib, as a targeted therapy, produced a substantial overall survival benefit in patients with previously treated metastatic pancreatic cancer compared with standard chemotherapy, aligning with prior findings.
Goldsmith added that the data could mark a major advance for patients and highlight the drug’s potential to reshape treatment approaches. He said the company is progressing quickly toward global regulatory filings and remains focused on accelerating the development of the therapy for patients across a wide range of RAS-driven cancers.
Revolution Medicines is heavily reliant on the success of daraxonrasib, which Evaluate recently ranked as the most valuable orphan drug candidate currently in development across the biopharma industry. Analysts at Evaluate projected the therapy could generate around $4 billion in annual sales by 2032, citing the significant unmet need in pancreatic cancer – an area where immunotherapies have largely fallen short.
The company has already capitalized on growing investor enthusiasm, securing a financing agreement with Royalty Pharma that could bring in up to $2 billion in exchange for a share of future revenues if the drug reaches the market.
Revolution Medicines has emphasized that pancreatic cancer is particularly dependent on RAS signaling, with mutations present in more than 90% of cases. As a multi-selective inhibitor targeting active RAS(ON) proteins, daraxonrasib is designed to address a broad spectrum of RAS-driven tumors.
In parallel, the biotech is advancing another phase 3 study evaluating daraxonrasib both as a standalone treatment and in combination with chemotherapy in first-line PDAC patients. The decision to move forward with this trial followed earlier data showing a 55% overall response rate in patients with newly diagnosed metastatic PDAC treated with the combination regimen.
RAS Trial Achieves Key Survival Endpoints
In the latest update, the RAS inhibitor developed by Revolution Medicines demonstrated statistically significant improvements in overall survival. These findings highlight the growing potential of RAS-targeted therapies, especially in cancers where traditional treatments have shown limited effectiveness.
Beyond meeting primary endpoints, the study also revealed encouraging secondary outcomes that strengthen confidence in the therapy’s overall benefit. Patients receiving the treatment showed delayed disease progression and improved response durability compared to standard-of-care options. These findings suggest that the drug may not only extend life but also enhance quality of life over time.
Notably, the safety profile remained manageable throughout the trial. Most adverse events were consistent with expectations for targeted oncology therapies, and discontinuation rates were relatively low. This balance between efficacy and tolerability is critical for long-term treatment adoption in real-world settings.
Scientific Innovation Behind the Therapy
The success of this program reflects years of progress in precision medicine and structure-based drug design. Researchers have refined their understanding of how cancer-driving mutations alter protein behavior, enabling the development of compounds that can selectively bind and inhibit previously “undruggable” targets.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
